Le Lézard
Classified in: Health
Subjects: TDS, FVT

NuVasive To Present At The 36th Annual J.P. Morgan Healthcare Conference



SAN DIEGO, Jan. 3, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will present at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Monday, Jan. 8, 2018, at 1:30 p.m. PT / 4:30 p.m. ET.

NuVasive Logo

A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the applicable live webcast.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.


These press releases may also interest you

at 18:00
Boys Town National Research Hospital ("Boys Town") is providing notice to current and former patients and employees of a recent incident involving personal information. To date, Boys Town has not received any reports that personal information has...

at 17:30
Chronic Care Management, Inc. announced today that is has made two leadership team appointments. Gurpreet Singh becomes the company's new Chief Information Officer, and Marc Gauthier is the company's new Head of Enterprise Business Development. Dr....

at 17:00
MedReleaf Corp. ("MedReleaf") today announced that the Ontario Superior Court of Justice (Commercial List) has issued a final order approving its previously announced plan of arrangement (the "Arrangement") pursuant to which Aurora Cannabis Inc....

at 17:00
Institute on Aging  ("IOA") has become aware of a data security incident that may have involved the personal and protected health information of some of its clients and employees. IOA has sent notification to the potentially involved clients to...

at 16:45
The "Infusion Pump Market by Product, Application, End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering. The infusion pumps market is expected to reach USD 15.89 billion by 2023 from USD 11.9 billion in...

at 16:30
Madenco Biosciences Inc. ("Madenco"), a subsidiary of Quest PharmaTech Inc. ("Quest"), today announces that it will no longer actively promote consumer health products, in order to focus on development of pharmaceutical products.  Madenco will no...




News published on 3 january 2018 at 16:02 and distributed by: